Breaking News, Collaborations & Alliances

Silence Therapeutics Earns $10M AZ Milestone in siRNA Alliance

AstraZeneca selects the first product candidate to advance development in multi-target collaboration.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca has selected the first product candidate under its siRNA (short interfering RNA) collaboration with Silence Therapeutics and will pay Silence a $10 million option fee to advance development on an undisclosed program. Silence Therapeutics is a biotechnology company working to silence diseases through precision engineered medicines.   Silence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence’s mRNAi GOLD platform to develop siRNA therapeuti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters